

Carolina Solis-Herrera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5370689/publications.pdf>

Version: 2024-02-01

21
papers

1,466
citations

687363

13
h-index

713466

21
g-index

21
all docs

21
docs citations

21
times ranked

2200
citing authors

#	ARTICLE	IF	CITATIONS
1	Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose. <i>Diabetes Care</i> , 2022, 45, 1372-1380.	8.6	4
2	Effect of Mild Physiologic Hyperglycemia on Insulin Secretion, Insulin Clearance, and Insulin Sensitivity in Healthy Glucose-Tolerant Subjects. <i>Diabetes</i> , 2021, 70, 204-213.	0.6	15
3	Therapeutic Manipulation of Myocardial Metabolism. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2022-2039.	2.8	40
4	Cardioprotective Effects of Pioglitazone in Type 2 Diabetes. <i>Diabetes Spectrum</i> , 2021, 34, 243-247.	1.0	1
5	Antihyperglycemic Algorithms for Type 2 Diabetes: Focus on Nonglycemic Outcomes. <i>Diabetes Spectrum</i> , 2021, 34, 248-256.	1.0	1
6	A new perspective on lowering CV risk from hypoglycaemia. <i>European Heart Journal</i> , 2020, 41, 218-220.	2.2	6
7	Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin. <i>Diabetes Care</i> , 2020, 43, 2519-2527.	8.6	3
8	Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy. <i>Diabetologia</i> , 2020, 63, 2423-2433.	6.3	17
9	Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion. <i>Diabetes Care</i> , 2020, 43, 1065-1069.	8.6	15
10	Empagliflozin Treatment Is Associated With Improved β -Cell Function in Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1402-1407.	3.6	63
11	Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes. <i>Diabetes Care</i> , 2017, 40, 1530-1536.	8.6	45
12	Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, 2036-2041.	8.6	155
13	Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1249-1256.	3.6	30
14	Dapagliflozin Lowers Plasma Glucose Concentration and Improves β -Cell Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1927-1932.	3.6	133
15	GLP-1 Receptor Agonists. <i>The Diabetes Educator</i> , 2015, 41, 32S-46S.	2.5	11
16	Assessment of Pancreatic β -Cell Function: Review of Methods and Clinical Applications. <i>Current Diabetes Reviews</i> , 2014, 10, 2-42.	1.3	179
17	Nephropathy in Youth and Young Adults with Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2014, 14, 456.	4.2	16
18	Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. <i>Journal of Clinical Investigation</i> , 2014, 124, 509-514.	8.2	661

#	ARTICLE	IF	CITATIONS
19	Inhibition of renal glucose reabsorption as a novel treatment for diabetes patients. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2014, 36, 80-92.	0.9	11
20	Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2756-2762.	8.6	52
21	Prevalence and Heritability of Clusters for Diagnostic Components of Metabolic Syndrome: The Oman Family Study. <i>Metabolic Syndrome and Related Disorders</i> , 2008, 6, 129-135.	1.3	8